Skip to main content
DR REDDYS LABORATORIES LTD logo

DR REDDYS LABORATORIES LTD — Investor Relations & Filings

Ticker · RDY ISIN · US2561352038 LEI · 335800OVDPY3DVZR2798 BSE.NS Manufacturing
Filings indexed 2,318 across all filing types
Latest filing 2024-11-05 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS RDY

About DR REDDYS LABORATORIES LTD

https://www.drreddys.com/

Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company focused on providing affordable and innovative medicines. The company's core activities include the development, manufacturing, and marketing of a broad portfolio of products. This portfolio encompasses Active Pharmaceutical Ingredients (APIs), generic and branded-generic formulations, over-the-counter (OTC) products, and biologics. In addition to its significant presence in the generics market, the company invests in the research and development of novel molecules and proprietary products, with a focus on therapeutic areas such as dermatology and neurology. Dr. Reddy's is also committed to sustainable operations, actively working to reduce its environmental footprint through initiatives in water conservation, waste reduction, and decarbonisation.

Recent filings

Filing Released Lang Actions
Unaudited Financial results for the quarter and half-year ended September 30, 2024
Interim / Quarterly Report Classification · 95% confidence The document is a detailed disclosure from Dr. Reddy's Laboratories Limited dated November 5, 2024, addressed to multiple stock exchanges. It reports the approval of unaudited consolidated and standalone financial results for the quarter and half-year ended September 30, 2024, prepared under IFRS and Indian Accounting Standards. It includes extensive financial data such as revenues, segment information, profit and loss details, and statements of financial position. The document also mentions limited review reports by statutory auditors, which is typical for interim or quarterly financial results. The presence of detailed financial statements and notes confirms this is a comprehensive interim financial report rather than a brief earnings release or an announcement of results. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2025
2024-11-05 English
FORM 6-K
Regulatory Filings
2024-11-04 English
Grant of Employee Stock Options
Share Issue/Capital Change Classification · 95% confidence The document is a disclosure under Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, informing about the grant of stock options to employees under the Employees Stock Option Schemes. It is an announcement related to stock options granted by the company, which pertains to capital changes but is not a full financial report or detailed capital structure update. The document is short (1366 characters) and serves as an official notification of a capital-related event (stock option grant). Therefore, it fits best under the category of Share Issue/Capital Change (SHA).
2024-11-04 English
FORM 6-K
Regulatory Filings
2024-10-29 English
Update on Stock Split
Share Issue/Capital Change Classification · 100% confidence The document is a formal letter addressed to stock exchanges providing an update on a stock split, detailing the pre and post subdivision share capital structure. It does not contain financial statements, earnings data, or detailed financial analysis. The document is short (1882 characters) and serves as an announcement of a capital change event (stock split). Therefore, it fits the category of Share Issue/Capital Change (SHA).
2024-10-29 English
Regulatory Filings 2024
Regulatory Filings
2024-10-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.